Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment

NCT07545486 is registered in ClinicalTrials.gov with Chirec as lead sponsor.

NCT NCT07545486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment
Lead sponsor
Chirec
Phase
Observational
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 1, 2036
Enrollment
1,235 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor